NS5B polymerase inhibitor

0 marketed 1 in Phase 3 1 in Phase 2

This page covers all NS5B polymerase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HCV NS5B RNA-dependent RNA polymerase, NS5B polymerase.

Targets

HCV NS5B RNA-dependent RNA polymerase · NS5B polymerase

Phase 3 pipeline (1)

DCV · Bristol-Myers Squibb · Virology / Hepatology
DCV is a direct-acting antiviral agent that inhibits the hepatitis C virus NS5B RNA-dependent RNA polymerase, blocking viral replication.

Phase 2 pipeline (1)

ANA598 · Hoffmann-La Roche · Infectious Diseases
ANA598 is a non-nucleoside inhibitor of the NS5B polymerase of the hepatitis C virus.